Emre Vural
Concepts (314)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 19 | 2025 | 291 | 2.650 |
Why?
| | Free Tissue Flaps | 9 | 2024 | 63 | 1.610 |
Why?
| | Mandibular Fractures | 5 | 2013 | 7 | 1.560 |
Why?
| | Surgical Flaps | 8 | 2023 | 110 | 1.530 |
Why?
| | Skin Transplantation | 7 | 2010 | 43 | 1.260 |
Why?
| | Oropharyngeal Neoplasms | 2 | 2024 | 19 | 1.210 |
Why?
| | Fracture Fixation, Internal | 4 | 2013 | 45 | 1.030 |
Why?
| | Graft Survival | 6 | 2019 | 157 | 1.030 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2024 | 647 | 0.950 |
Why?
| | Rhinoplasty | 3 | 2012 | 10 | 0.930 |
Why?
| | Retrospective Studies | 33 | 2025 | 6819 | 0.910 |
Why?
| | Enteral Nutrition | 2 | 2024 | 157 | 0.870 |
Why?
| | Physical Examination | 1 | 2024 | 96 | 0.820 |
Why?
| | Deglutition | 1 | 2024 | 45 | 0.820 |
Why?
| | Deglutition Disorders | 1 | 2024 | 76 | 0.790 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2009 | 189 | 0.780 |
Why?
| | Sensitivity and Specificity | 3 | 2024 | 867 | 0.760 |
Why?
| | Tomography, X-Ray Computed | 4 | 2024 | 1180 | 0.710 |
Why?
| | Recurrent Laryngeal Nerve Injuries | 1 | 2021 | 6 | 0.710 |
Why?
| | Carcinoma, Squamous Cell | 7 | 2024 | 332 | 0.700 |
Why?
| | Robotics | 1 | 2021 | 43 | 0.670 |
Why?
| | Skin | 6 | 2010 | 419 | 0.660 |
Why?
| | Facial Paralysis | 2 | 2019 | 25 | 0.650 |
Why?
| | Bone Plates | 2 | 2013 | 17 | 0.650 |
Why?
| | Mandibular Reconstruction | 3 | 2024 | 15 | 0.620 |
Why?
| | Middle Aged | 30 | 2025 | 13419 | 0.610 |
Why?
| | Nasolabial Fold | 1 | 2019 | 1 | 0.610 |
Why?
| | Fracture Fixation | 2 | 2012 | 18 | 0.590 |
Why?
| | Humans | 57 | 2025 | 53230 | 0.590 |
Why?
| | Postoperative Complications | 9 | 2025 | 1099 | 0.580 |
Why?
| | Male | 37 | 2025 | 27435 | 0.570 |
Why?
| | Pharyngeal Diseases | 2 | 2025 | 16 | 0.550 |
Why?
| | Neck | 5 | 2021 | 97 | 0.540 |
Why?
| | Aged | 21 | 2025 | 10429 | 0.530 |
Why?
| | Skin, Artificial | 2 | 2007 | 11 | 0.510 |
Why?
| | Female | 35 | 2025 | 28782 | 0.500 |
Why?
| | Adult | 22 | 2025 | 14534 | 0.490 |
Why?
| | Mandible | 2 | 2024 | 25 | 0.470 |
Why?
| | Wound Healing | 4 | 2010 | 226 | 0.470 |
Why?
| | Collagen | 2 | 2007 | 215 | 0.460 |
Why?
| | Neck Dissection | 4 | 2021 | 30 | 0.450 |
Why?
| | Recurrent Laryngeal Nerve | 2 | 2021 | 12 | 0.450 |
Why?
| | Laryngeal Nerves | 2 | 2021 | 15 | 0.450 |
Why?
| | Treatment Outcome | 15 | 2025 | 5595 | 0.440 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2010 | 62 | 0.390 |
Why?
| | Laryngectomy | 3 | 2010 | 27 | 0.390 |
Why?
| | Hypopharyngeal Neoplasms | 1 | 2012 | 8 | 0.380 |
Why?
| | Tracheotomy | 1 | 2012 | 15 | 0.380 |
Why?
| | Forehead | 1 | 2012 | 8 | 0.370 |
Why?
| | Gastrostomy | 1 | 2012 | 56 | 0.370 |
Why?
| | Device Removal | 1 | 2013 | 89 | 0.360 |
Why?
| | Chemoradiotherapy | 1 | 2012 | 50 | 0.360 |
Why?
| | Nose | 1 | 2012 | 33 | 0.360 |
Why?
| | Length of Stay | 3 | 2024 | 684 | 0.350 |
Why?
| | Laser Therapy | 2 | 2011 | 75 | 0.340 |
Why?
| | Rhytidoplasty | 1 | 2011 | 6 | 0.340 |
Why?
| | Thyroidectomy | 2 | 2021 | 61 | 0.330 |
Why?
| | Lasers | 2 | 2007 | 64 | 0.330 |
Why?
| | Face | 1 | 2011 | 56 | 0.330 |
Why?
| | Follow-Up Studies | 7 | 2023 | 2318 | 0.320 |
Why?
| | Laryngeal Neoplasms | 2 | 2007 | 44 | 0.320 |
Why?
| | Cutaneous Fistula | 1 | 2010 | 14 | 0.310 |
Why?
| | Aged, 80 and over | 9 | 2024 | 3494 | 0.310 |
Why?
| | Skin Neoplasms | 3 | 2024 | 500 | 0.310 |
Why?
| | Rhinophyma | 1 | 2009 | 1 | 0.310 |
Why?
| | Fistula | 1 | 2010 | 26 | 0.310 |
Why?
| | Hemostasis, Surgical | 1 | 2009 | 11 | 0.310 |
Why?
| | Surgical Instruments | 1 | 2009 | 29 | 0.300 |
Why?
| | Molar | 1 | 2009 | 3 | 0.300 |
Why?
| | Biocompatible Materials | 2 | 2007 | 67 | 0.300 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2008 | 26 | 0.290 |
Why?
| | Port-Wine Stain | 1 | 2008 | 14 | 0.290 |
Why?
| | Quality of Life | 2 | 2012 | 902 | 0.280 |
Why?
| | Tinea | 1 | 2007 | 2 | 0.270 |
Why?
| | Arthrodermataceae | 1 | 2007 | 4 | 0.270 |
Why?
| | Trichophyton | 1 | 2007 | 4 | 0.270 |
Why?
| | Colony Count, Microbial | 1 | 2007 | 59 | 0.270 |
Why?
| | Resins, Synthetic | 1 | 2007 | 2 | 0.270 |
Why?
| | External Fixators | 1 | 2007 | 10 | 0.260 |
Why?
| | Computer-Aided Design | 1 | 2007 | 20 | 0.260 |
Why?
| | Nose Deformities, Acquired | 1 | 2007 | 2 | 0.260 |
Why?
| | Lasers, Solid-State | 1 | 2007 | 31 | 0.260 |
Why?
| | Nasal Septum | 1 | 2007 | 8 | 0.260 |
Why?
| | Models, Anatomic | 1 | 2007 | 40 | 0.260 |
Why?
| | Patient Care Planning | 1 | 2007 | 69 | 0.250 |
Why?
| | Time-to-Treatment | 2 | 2025 | 81 | 0.250 |
Why?
| | Chi-Square Distribution | 4 | 2012 | 291 | 0.250 |
Why?
| | Predictive Value of Tests | 2 | 2024 | 934 | 0.240 |
Why?
| | Dermis | 1 | 2006 | 19 | 0.240 |
Why?
| | Retropharyngeal Abscess | 1 | 2025 | 4 | 0.240 |
Why?
| | Abscess | 1 | 2025 | 43 | 0.230 |
Why?
| | Carcinoma | 3 | 2024 | 136 | 0.230 |
Why?
| | Drainage | 1 | 2025 | 92 | 0.230 |
Why?
| | Carcinoma, Merkel Cell | 2 | 2016 | 41 | 0.220 |
Why?
| | Prospective Studies | 4 | 2024 | 2411 | 0.220 |
Why?
| | Osteoradionecrosis | 1 | 2024 | 6 | 0.220 |
Why?
| | Mandibular Diseases | 1 | 2024 | 11 | 0.220 |
Why?
| | Mandibular Condyle | 1 | 2004 | 4 | 0.220 |
Why?
| | Reoperation | 2 | 2021 | 476 | 0.210 |
Why?
| | Salivary Gland Neoplasms | 1 | 2024 | 8 | 0.210 |
Why?
| | Skull | 1 | 2024 | 75 | 0.210 |
Why?
| | Fluoroscopy | 1 | 2024 | 49 | 0.210 |
Why?
| | Scalp | 1 | 2024 | 44 | 0.210 |
Why?
| | Video Recording | 1 | 2024 | 81 | 0.210 |
Why?
| | Head | 3 | 2021 | 72 | 0.200 |
Why?
| | Operative Time | 1 | 2023 | 78 | 0.200 |
Why?
| | Scapula | 1 | 2023 | 16 | 0.200 |
Why?
| | Surgery, Computer-Assisted | 1 | 2023 | 54 | 0.200 |
Why?
| | Tramadol | 1 | 2022 | 30 | 0.190 |
Why?
| | Intraoperative Care | 1 | 2021 | 51 | 0.180 |
Why?
| | Glossectomy | 1 | 2021 | 5 | 0.180 |
Why?
| | Tongue | 1 | 2021 | 40 | 0.170 |
Why?
| | Hypotension | 1 | 2021 | 62 | 0.170 |
Why?
| | Chylothorax | 1 | 2021 | 18 | 0.170 |
Why?
| | Nuclear Proteins | 2 | 2015 | 250 | 0.170 |
Why?
| | Vasoconstrictor Agents | 1 | 2021 | 81 | 0.170 |
Why?
| | Arteries | 1 | 2021 | 93 | 0.170 |
Why?
| | Venous Thrombosis | 1 | 2021 | 91 | 0.160 |
Why?
| | Morbidity | 1 | 2021 | 132 | 0.160 |
Why?
| | Intraoperative Complications | 1 | 2021 | 114 | 0.160 |
Why?
| | Health Services Accessibility | 1 | 2025 | 477 | 0.160 |
Why?
| | Acetaminophen | 1 | 2022 | 277 | 0.160 |
Why?
| | Rats, Sprague-Dawley | 3 | 2009 | 1544 | 0.150 |
Why?
| | Random Allocation | 2 | 2010 | 284 | 0.150 |
Why?
| | Health Status Indicators | 1 | 2019 | 80 | 0.150 |
Why?
| | Analgesics, Opioid | 2 | 2022 | 622 | 0.140 |
Why?
| | Recovery of Function | 2 | 2012 | 203 | 0.140 |
Why?
| | Time Factors | 4 | 2012 | 2991 | 0.140 |
Why?
| | Neovascularization, Physiologic | 2 | 2009 | 86 | 0.130 |
Why?
| | Patient Satisfaction | 1 | 2019 | 292 | 0.130 |
Why?
| | Heart Defects, Congenital | 1 | 2023 | 625 | 0.130 |
Why?
| | Rats | 3 | 2009 | 3162 | 0.130 |
Why?
| | Animals | 7 | 2016 | 13526 | 0.130 |
Why?
| | Risk Assessment | 2 | 2012 | 1368 | 0.120 |
Why?
| | Arkansas | 3 | 2025 | 2068 | 0.120 |
Why?
| | Benzoxazoles | 1 | 2016 | 11 | 0.120 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2016 | 83 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-myb | 1 | 2015 | 8 | 0.110 |
Why?
| | Cell Proliferation | 2 | 2016 | 1031 | 0.110 |
Why?
| | Comorbidity | 2 | 2019 | 638 | 0.110 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2025 | 65 | 0.110 |
Why?
| | Pyrimidines | 1 | 2016 | 205 | 0.110 |
Why?
| | Cohort Studies | 2 | 2024 | 1557 | 0.110 |
Why?
| | Fibula | 2 | 2024 | 23 | 0.110 |
Why?
| | Adolescent | 4 | 2009 | 6907 | 0.100 |
Why?
| | Apoptosis | 2 | 2016 | 1139 | 0.100 |
Why?
| | Neoplasm Staging | 2 | 2024 | 774 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2015 | 868 | 0.100 |
Why?
| | Survival Analysis | 2 | 2012 | 659 | 0.100 |
Why?
| | Jaw Fixation Techniques | 1 | 2012 | 1 | 0.100 |
Why?
| | Cancer Care Facilities | 1 | 2012 | 20 | 0.100 |
Why?
| | Multiple Trauma | 1 | 2012 | 30 | 0.090 |
Why?
| | Cartilage | 1 | 2012 | 47 | 0.090 |
Why?
| | Leukoplakia, Oral | 1 | 2011 | 6 | 0.090 |
Why?
| | Aminolevulinic Acid | 1 | 2011 | 9 | 0.090 |
Why?
| | Lasers, Dye | 1 | 2011 | 10 | 0.090 |
Why?
| | Photosensitizing Agents | 1 | 2011 | 21 | 0.090 |
Why?
| | Transcription Factors | 1 | 2015 | 571 | 0.090 |
Why?
| | Thyroid Gland | 2 | 2022 | 76 | 0.090 |
Why?
| | Epigenesis, Genetic | 1 | 2015 | 412 | 0.090 |
Why?
| | Critical Pathways | 2 | 2023 | 36 | 0.090 |
Why?
| | Photochemotherapy | 1 | 2011 | 32 | 0.090 |
Why?
| | Rotation | 1 | 2011 | 44 | 0.080 |
Why?
| | Taxoids | 1 | 2010 | 38 | 0.080 |
Why?
| | Drug Resistance, Multiple | 1 | 2010 | 25 | 0.080 |
Why?
| | Pain, Postoperative | 2 | 2022 | 169 | 0.080 |
Why?
| | Granulation Tissue | 1 | 2010 | 9 | 0.080 |
Why?
| | DNA, Neoplasm | 1 | 2011 | 146 | 0.080 |
Why?
| | Mice, Knockout | 2 | 2010 | 910 | 0.080 |
Why?
| | Epigenomics | 1 | 2011 | 76 | 0.080 |
Why?
| | Tissue and Organ Harvesting | 1 | 2010 | 25 | 0.080 |
Why?
| | Neoplastic Stem Cells | 1 | 2011 | 90 | 0.080 |
Why?
| | Myeloid Cells | 1 | 2010 | 45 | 0.080 |
Why?
| | Pectoralis Muscles | 1 | 2010 | 6 | 0.080 |
Why?
| | Biopsy, Fine-Needle | 1 | 2010 | 104 | 0.080 |
Why?
| | Probability | 1 | 2010 | 171 | 0.080 |
Why?
| | Neoplasm Invasiveness | 2 | 2007 | 281 | 0.080 |
Why?
| | Risk Factors | 2 | 2024 | 4017 | 0.080 |
Why?
| | Statistics, Nonparametric | 2 | 2007 | 198 | 0.080 |
Why?
| | Microsatellite Instability | 1 | 2009 | 21 | 0.080 |
Why?
| | Mice | 4 | 2016 | 5982 | 0.080 |
Why?
| | Esthetics | 1 | 2009 | 12 | 0.080 |
Why?
| | Ultrasonography, Interventional | 1 | 2010 | 138 | 0.080 |
Why?
| | Gene Silencing | 1 | 2009 | 122 | 0.080 |
Why?
| | Tooth Extraction | 1 | 2009 | 6 | 0.080 |
Why?
| | Graft Rejection | 1 | 2010 | 166 | 0.070 |
Why?
| | Immunohistochemistry | 2 | 2009 | 975 | 0.070 |
Why?
| | Blood Loss, Surgical | 1 | 2009 | 66 | 0.070 |
Why?
| | Paraffin Embedding | 1 | 2008 | 52 | 0.070 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2009 | 202 | 0.070 |
Why?
| | Bone Wires | 1 | 2008 | 4 | 0.070 |
Why?
| | Arteriovenous Malformations | 1 | 2009 | 75 | 0.070 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2010 | 350 | 0.070 |
Why?
| | Mice, Inbred C57BL | 2 | 2010 | 1925 | 0.070 |
Why?
| | Quinones | 1 | 2007 | 9 | 0.070 |
Why?
| | Photomicrography | 1 | 2007 | 6 | 0.070 |
Why?
| | Dental Occlusion | 1 | 2007 | 2 | 0.070 |
Why?
| | Mandibular Neoplasms | 1 | 2007 | 6 | 0.070 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2007 | 6 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 579 | 0.070 |
Why?
| | Skull Base Neoplasms | 1 | 2007 | 20 | 0.070 |
Why?
| | Jaw Diseases | 1 | 2007 | 6 | 0.070 |
Why?
| | Ear Cartilage | 1 | 2007 | 5 | 0.070 |
Why?
| | Osteotomy | 1 | 2007 | 32 | 0.060 |
Why?
| | Bone Transplantation | 1 | 2007 | 43 | 0.060 |
Why?
| | Osteonecrosis | 1 | 2007 | 35 | 0.060 |
Why?
| | Macrophages | 1 | 2009 | 380 | 0.060 |
Why?
| | Sesquiterpenes | 1 | 2007 | 90 | 0.060 |
Why?
| | Salvage Therapy | 2 | 2022 | 138 | 0.060 |
Why?
| | MicroRNAs | 1 | 2010 | 397 | 0.060 |
Why?
| | Blood Vessels | 1 | 2007 | 73 | 0.060 |
Why?
| | Bone Density Conservation Agents | 1 | 2007 | 75 | 0.060 |
Why?
| | Equipment Design | 1 | 2007 | 290 | 0.060 |
Why?
| | Logistic Models | 1 | 2009 | 947 | 0.060 |
Why?
| | Analysis of Variance | 1 | 2007 | 547 | 0.060 |
Why?
| | Diphosphonates | 1 | 2007 | 92 | 0.060 |
Why?
| | Transplantation, Heterologous | 1 | 2006 | 78 | 0.060 |
Why?
| | Swine | 1 | 2007 | 440 | 0.060 |
Why?
| | Models, Theoretical | 1 | 2007 | 180 | 0.060 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2007 | 235 | 0.060 |
Why?
| | Pilot Projects | 2 | 2022 | 726 | 0.060 |
Why?
| | Severity of Illness Index | 1 | 2009 | 1049 | 0.060 |
Why?
| | Azepines | 2 | 2016 | 21 | 0.060 |
Why?
| | Microsurgery | 2 | 2021 | 32 | 0.060 |
Why?
| | Combined Modality Therapy | 2 | 2024 | 640 | 0.060 |
Why?
| | Stress, Mechanical | 1 | 2006 | 95 | 0.060 |
Why?
| | Hypoglossal Nerve | 1 | 2005 | 4 | 0.060 |
Why?
| | Mouth | 1 | 2025 | 36 | 0.060 |
Why?
| | Carotid Arteries | 1 | 2005 | 77 | 0.060 |
Why?
| | Disease Models, Animal | 1 | 2010 | 1517 | 0.060 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2016 | 228 | 0.060 |
Why?
| | Triazoles | 2 | 2016 | 114 | 0.060 |
Why?
| | Fracture Healing | 1 | 2004 | 28 | 0.050 |
Why?
| | Erythrocyte Transfusion | 1 | 2024 | 53 | 0.050 |
Why?
| | Range of Motion, Articular | 1 | 2004 | 110 | 0.050 |
Why?
| | Endoscopy | 1 | 2004 | 128 | 0.050 |
Why?
| | Blood Transfusion | 1 | 2024 | 127 | 0.050 |
Why?
| | Forearm | 1 | 2023 | 30 | 0.050 |
Why?
| | Vascular Surgical Procedures | 1 | 2005 | 171 | 0.050 |
Why?
| | Ambulatory Care Facilities | 1 | 2023 | 121 | 0.050 |
Why?
| | Ibuprofen | 1 | 2022 | 24 | 0.050 |
Why?
| | Tumor Cells, Cultured | 2 | 2016 | 441 | 0.050 |
Why?
| | Ambulatory Care | 1 | 2023 | 239 | 0.040 |
Why?
| | Anastomosis, Surgical | 1 | 2021 | 69 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 2021 | 211 | 0.040 |
Why?
| | Neoplasms, Squamous Cell | 2 | 2011 | 7 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 370 | 0.040 |
Why?
| | Promoter Regions, Genetic | 2 | 2015 | 465 | 0.040 |
Why?
| | Odds Ratio | 1 | 2021 | 567 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 1 | 2007 | 1583 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2023 | 1219 | 0.040 |
Why?
| | Child, Preschool | 1 | 2008 | 4162 | 0.040 |
Why?
| | Pain Management | 1 | 2021 | 185 | 0.040 |
Why?
| | Child | 2 | 2009 | 7379 | 0.040 |
Why?
| | Prognosis | 1 | 2024 | 2118 | 0.040 |
Why?
| | Cell Line, Tumor | 2 | 2015 | 1470 | 0.040 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 1043 | 0.030 |
Why?
| | Patient Readmission | 1 | 2019 | 251 | 0.030 |
Why?
| | Patient Discharge | 1 | 2019 | 325 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2016 | 90 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 2016 | 134 | 0.030 |
Why?
| | Drug Synergism | 1 | 2016 | 147 | 0.030 |
Why?
| | Mice, SCID | 1 | 2016 | 180 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 181 | 0.030 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2015 | 20 | 0.030 |
Why?
| | Infant | 1 | 2024 | 3805 | 0.030 |
Why?
| | Acetylation | 1 | 2015 | 97 | 0.030 |
Why?
| | Enhancer Elements, Genetic | 1 | 2015 | 60 | 0.030 |
Why?
| | Blotting, Western | 1 | 2016 | 587 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 405 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2015 | 237 | 0.030 |
Why?
| | Chromatin | 1 | 2015 | 145 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2015 | 170 | 0.030 |
Why?
| | Protein Binding | 1 | 2015 | 670 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2016 | 1133 | 0.020 |
Why?
| | Administration, Topical | 1 | 2011 | 62 | 0.020 |
Why?
| | Pharmacogenetics | 1 | 2010 | 52 | 0.020 |
Why?
| | Treatment Failure | 1 | 2010 | 119 | 0.020 |
Why?
| | Deferoxamine | 1 | 2009 | 8 | 0.020 |
Why?
| | Biopsy | 1 | 2011 | 600 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2010 | 211 | 0.020 |
Why?
| | Drug Combinations | 1 | 2009 | 138 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2011 | 400 | 0.020 |
Why?
| | Keratinocytes | 1 | 2009 | 91 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2009 | 88 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 452 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2009 | 203 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 1367 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2009 | 233 | 0.020 |
Why?
| | Cranial Nerve Neoplasms | 1 | 2007 | 6 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2007 | 31 | 0.020 |
Why?
| | Radiographic Image Enhancement | 1 | 2007 | 29 | 0.020 |
Why?
| | False Positive Reactions | 1 | 2007 | 66 | 0.020 |
Why?
| | Curettage | 1 | 2007 | 12 | 0.020 |
Why?
| | Dental Care | 1 | 2007 | 11 | 0.020 |
Why?
| | Image Enhancement | 1 | 2007 | 49 | 0.020 |
Why?
| | Skin Temperature | 1 | 2007 | 17 | 0.020 |
Why?
| | Hyperbaric Oxygenation | 1 | 2007 | 15 | 0.020 |
Why?
| | Survival Rate | 1 | 2009 | 949 | 0.020 |
Why?
| | Imidazoles | 1 | 2007 | 114 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2007 | 116 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2009 | 1569 | 0.010 |
Why?
| | Contrast Media | 1 | 2007 | 178 | 0.010 |
Why?
| | Hot Temperature | 1 | 2007 | 202 | 0.010 |
Why?
| | DNA Methylation | 1 | 2009 | 592 | 0.010 |
Why?
| | Cadaver | 1 | 2005 | 90 | 0.010 |
Why?
| | Fluorouracil | 1 | 2004 | 59 | 0.010 |
Why?
| | Lymph Node Excision | 1 | 2004 | 132 | 0.010 |
Why?
| | Cisplatin | 1 | 2004 | 282 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2010 | 1232 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 2007 | 830 | 0.010 |
Why?
| | Young Adult | 1 | 2009 | 4511 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2004 | 1723 | 0.010 |
Why?
| | Multiple Myeloma | 1 | 2007 | 3082 | 0.010 |
Why?
|
|
Vural's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|